AbbVie (ABBV) Tops Q4 EPS by 4c, Raises FY18 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
BMO Capital Downgrades Abbvie (ABBV) to Underperform; 'Risk/Reward Skewed to the Downside'
January 29, 2018 7:34 AM ESTBMO Capital downgraded Abbvie (NYSE: ABBV) from Market Perform to Underperform with a price target of $95.00 (from $84.00).
Analyst Alex Arfaei commented, "Our thesis is unchanged, but the risk/reward in ABBV has meaningfully changed after its remarkable rise, leading us to... More
UPDATE: Leerink Partners Downgrades Abbvie (ABBV) to Market Perform, 'Limited Upside After Huge Run'
January 29, 2018 6:39 AM EST(Updated - January 29, 2018 7:18 AM EST)
(updated to add analyst comment)
Leerink Partners downgraded Abbvie (NYSE: ABBV) from Outperform to Market Perform with a price target of $127.00 (from $105.00).
Analyst Geoffrey Porges comments "After the dramatic move in AbbVies stock on... More
Abbvie (ABBV) PT Raised to $157 at SunTrust Robinson Humphrey; Premium Warranted
January 29, 2018 6:14 AM ESTSunTrust Robinson Humphrey raised its price target on Abbvie (NYSE: ABBV) to $157.00 (from $105.00) while maintaining a Buy rating.
Analyst John Boris said operational execution and pipeline warrant a premium.
... MoreAbbvie (ABBV) PT Raised to $130 at Cowen; Big Beat
January 26, 2018 11:16 AM ESTCowen raised its price target on Abbvie (NYSE: ABBV) to $130.00 (from $105.00) while maintaining an Outperform rating.
Analyst Steve Scala commented, "Q4 EPS and revenue well ahead of estimates. 2018 EPS guidance boosted sizably on strong operations and tax rate benefits. Plans for increasing shareholder... More
